What Sever Pharma Solutions does

Sever Pharma Solutions is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Malmö, Sweden, with a wholly owned US subsidiary in Putnam, Connecticut (Foster Delivery Science, acquired 2021) and a sales office in Baarn, Netherlands. Founded in 1975 as part of Ferrosan, the company has operated under several corporate parents (Pharmacia, Ferring, QPharma) and is currently owned by Nordic Group BV, having rebranded to its current name in 2021. The company employs approximately 380 people globally and operates roughly 38,300 square meters of facility space across its two main manufacturing sites.

The company's core offering is end-to-end pharmaceutical development and manufacturing services built around four integrated pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These are enabled by six technical capabilities: Hot Melt Extrusion (HME) for bioavailability enhancement of BCS Class II/IV molecules, injection molding, controlled-release polymer-based dosage forms, solid dosage forms, aseptic fill and finish, and high-potency handling up to OEB6. The product portfolio is anchored on four categories: high-potent/cytotoxic/hormonal drug product manufacturing (including DEA Schedule 3-5 controlled substances), polymer-based delivery systems (implants, vaginal rings, intrauterine systems, intratumoral and ocular implants down to 100s of microns), hot melt extrusion for bioavailability enhancement, and prefilled syringe and autoinjector assembly. Sever Pharma Solutions is differentiated by a library of over 100 twin-screw extrusion designs, co-extrusion technology for multi-layer reservoir and matrix systems, and multi-jurisdictional GMP certification (FDA, EMA, Swedish MPA).

The business model is B2B enterprise contract services for pharmaceutical and biotech clients requiring specialized polymer-based drug delivery and high-potency containment. Revenue is generated through project-based contracts (development, clinical trial material production, technology transfer) and commercial supply agreements; pricing is quote-based and not publicly disclosed. Sever Pharma Solutions sells directly through an enterprise field sales motion and a global business development function led by Ulrike Foley, supplemented by presence at major industry conferences (CPhI Worldwide, DDF, Nordic Life Science Days, AAPS PharmSci360, Contract Pharma) and technical content marketing (whitepapers, videos, articles). Customer base spans pharmaceutical companies requiring CDMO services for complex delivery systems (hormone therapy, contraception, HIV prevention, oncology implants, pain therapeutics) and specialty biotechs developing novel formulations.

Name

Sever Pharma Solutions

Legal name

Sever Pharma Solutions

Website

https://severpharmasolutions.com

Company type

Private

Founded year

1975

Operating status

Operating

Short description

Sever Pharma Solutions is a privately held Swedish CDMO specializing in polymer-based drug delivery systems and high-potency (OEB6) pharmaceutical manufacturing, serving pharma and biotech clients globally from facilities in Sweden and the US.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Pharmaceutical CDMO services
• High potent drug manufacturing
• Polymer drug delivery systems
• Hot melt extrusion
• Aseptic fill finish

Headquarters

HQ city

Malmö

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Full-service CDMO providing end-to-end pharmaceutical development and manufacturing services including formulation development, clinical trial material production, analytical services, regulatory affairs support, and commercial manufacturing. Revenue generated through project-based contracts, technology transfer fees, and commercial supply agreements.
2. Commercial Product Manufacturing: Manufacturing and supply of pharmaceutical products including polymer-based dosage forms (vaginal rings, implants), solid dosage forms, and aseptically filled syringes. Revenue from commercial batch production and supply agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Sever Pharma Solutions is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides end-to-end development, analytical, regulatory, and manufacturing services for high-potency drug products and polymer-based controlled-release dosage forms. Its core offerings cover manufacturing of high potent APIs up to OEB6, polymer-based delivery systems (implants and vaginal rings), hot melt extrusion for bioavailability enhancement, and aseptic fill-and-finish for prefilled syringes and autoinjectors. Services span feasibility screening, formulation development, clinical trial material production, regulatory affairs support, and commercial supply for pharmaceutical and biotech clients globally.

Product overview

Sever Pharma Solutions is a Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs. The company operates a unified platform with four integrated service pillars: Development Services, Analytical Services, Regulatory Affairs Services, and Manufacturing Services. These services are enabled by six core technical capabilities: Hot Melt Extrusion, Injection Molding, High-Potent Dosage Forms, Controlled Release Polymer-Based Dosage Forms, Solid Dosage Forms, and Aseptic Fill and Finish. The product portfolio centers on four main offerings: High Potent Drug Product Manufacturing (handling APIs up to OEB6), Polymer-Based Delivery Systems (implants and vaginal rings), Hot Melt Extrusion for bioavailability enhancement, and Prefilled Syringes & Autoinjector Assembly. All capabilities are designed to work synergistically, enabling the company to support drug product development from early feasibility through clinical trials to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• High Potent Drug Product Manufacturing Contract manufacturing of pharmaceutical products containing highly potent APIs up to OEB6 (Occupational Exposure Band 6) and DEA Controlled Substances (Schedule 3-5), with advanced containment systems ensuring safe handling. Targeted at pharmaceutical and biotech clients requiring specialized high-potency manufacturing capabilities.
• Polymer-Based Delivery Systems Contract manufacturing of polymer-based implants and vaginal rings using extrusion, co-extrusion, and injection molding technologies for controlled and extended drug release. Targeted at pharmaceutical companies developing polymer-based sustained-release therapeutics in chronic disease, women's health, HIV prevention, and pain management.
• Hot Melt Extrusion Services Contract hot melt extrusion services for bioavailability enhancement of poorly water-soluble drugs (BCS Class II molecules), taste masking, and gastro protection of pH-sensitive drugs. Targeted at pharmaceutical clients requiring solubilization and solid dispersion formulation development.
• Prefilled Syringes and Autoinjector Assembly Contract manufacturing and fully automated assembly with visual inspection for prefilled syringes (0.2ml to 50ml) and autoinjectors, including high-potent and cytotoxic injectable drugs. Targeted at pharmaceutical companies needing sterile injectable drug-device combination product manufacturing.
• Pharmaceutical Development Services Pharmaceutical development services including feasibility screening, formulation development, clinical trial material production, and technology transfer designed with scale-up in mind. Targeted at pharmaceutical and biotech clients needing early to late-stage development support for complex dosage forms.
• Analytical Services cGMP analytical services including method development and validation, project support from early to late-stage development, commercial batch release testing, and stability testing for all ICH climatic zones. Targeted at pharmaceutical clients requiring comprehensive analytical and release testing for complex dosage forms.
• Regulatory Affairs Services Regulatory affairs expertise for polymeric dosage forms and drug-device combinations, supporting the development phase, registration process, and post-approval changes including CTD structure compilation. Targeted at pharmaceutical clients seeking regulatory pathway support for combination products across EU and US.
• Manufacturing Services Pharmaceutical manufacturing services including facility design, equipment selection, process development, technology transfers, serialization with aggregation via Tracelink interface for DSCSA and EU Falsified Medicines Directive compliance, and logistics. Targeted at pharmaceutical clients requiring end-to-end commercial manufacturing support.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

One partnership is on record.

• Silo PharmacoreStrategic or Co-development Partner · 14 August 2025Expanded partnership with Silo Pharma, Inc. (Nasdaq: SILO) for development of SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia. Sever Pharma Solutions is scaling up extrusion processes and continuing analytical testing. Previously supported earlier development stages including validation of delivery system through long-term in-vitro release testing and drug product characterization. If clinically successful, SP-26 could qualify for FDA's streamlined 505(b)(2) regulatory pathway.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hovione: Hovione is a specialty CDMO with deep expertise in HPAPI handling, hot melt extrusion, and aseptic fill-finish for injectables. It is the closest direct comparable to Sever in terms of high-potency and polymer-based drug delivery capabilities for small molecules.
• Recipharm: Recipharm is a Sweden-headquartered CDMO offering solid dose, sterile fill-finish, and high-potency manufacturing for pharma clients across Europe. Geographic and operational overlap make it a closely comparable European specialty CDMO peer.
• Aenova Group: Aenova is a European CDMO focused on solid dosage forms, including high-potency capabilities and injectables. Sever competes for similar pharmaceutical clients seeking integrated development-to-commercial services in Europe.
• PCI Pharma Services: PCI is a global CDMO with strong aseptic fill-finish, clinical-to-commercial supply, and serialization capabilities overlapping Sever's prefilled syringe and autoinjector assembly offerings.
• Eurofins CDMO: Eurofins' CDMO division offers formulation development, clinical manufacturing, and small-batch commercial supply for APIs and intermediates. It overlaps Sever's development services and analytical support offerings.

Broad incumbents

• Lonza CDMO: Lonza is a global top-tier CDMO with broad small-molecule and biologics capabilities, including aseptic fill-finish and high-potency containment. It is a broad incumbent rather than a niche specialist compared with Sever.
• Catalent (Novo Holdings): Catalent is one of the largest global CDMOs offering softgel, oral solid dose, biologics, and aseptic fill-finish. It is a broad incumbent competing for the same pharma client outsourcing budgets but across a much wider portfolio.
• Cambrex: Cambrex is a CDMO specializing in small-molecule API development and manufacturing with cGMP facilities. While it leans toward API rather than finished drug product, it competes for the same pharma CDMO wallet.

Emerging players

• Tapemark: Tapemark is a US-based contract manufacturer focused on transdermal patches and specialty drug delivery. Its polymer-based delivery focus and contract manufacturing model make it an emerging comparable in Sever's adjacent niche.
• Lifecore Biomedical: Lifecore is a CDMO specializing in sterile injectable fill-finish, prefilled syringes, and premium injectable manufacturing. It competes for similar aseptic and high-value injectable CDMO work but with a narrower product range than Sever.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCXmRz5YbUFrQVp3g2h_nKdQ
• LinkedInlinkedin.com/company/sever-pharma-solutions

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sever Pharma Solutions